Chemistry: analytical and immunological testing – Biological cellular material tested
Patent
1997-01-21
2000-03-21
Spector, Lorraine
Chemistry: analytical and immunological testing
Biological cellular material tested
530395, 530397, G01N 3348
Patent
active
060401877
DESCRIPTION:
BRIEF SUMMARY
FIELD OF TECHNOLOGY
The present invention relates to medicine, more specifically to the method of diagnostic evaluation of T-suppressors activity, namely, to the method for determining a suppressor component of human immune status and to the means for the realization thereof.
PRIOR ART
Known is .beta.-I-glycoprotein of placental origin which is a of trophoblastic .beta.-I-glycoprotein (TBG) used as a growth and proliferation stimulator for hematopoietic blood cells (U.S. Pat. No. 5,169,835, cl. A61K 35/50, 1989).
Nevertheless the known compound has not been used for determining a suppressor component of human immune status.
Known is the use of TBG for diagnosing and prognosticating the course of pregnancy (see L. G. Sotnikova et al., The Role of .beta.-I-glycopzotein Trophoblast in Diagnosing and Prognosticating Pregnancy, Metodicheskije Recomendatsii, Moscow, 1984). Nevertheless said work does not disclose the possibility of using TBG for diagnosing a suppressor component of human immune status.
Known is method for determining a suppressor component of human immune status which comprises collecting peripheral blood, obtaining a suspension of pure lymphocytes for cultivating test cultures with a suppression activator and without such activator, and further evaluating proliferation levels (see Dutton R. W. Inhibitory and Stimulatory Effects of Concanavalin A on the Response of Mouse Spleen Cells Suspensions to Antigen. J. Exp. Med., v.138, p.1496-1505, 1973).
Nevertheless the known method requires a hardly available and expensive foreign preparation, that is concanavalin A, as a suppression activator.
Known is a method for determining a suppressor component of human immune status which comprises collecting peripheral blood, obtaining a suspension of mononuclear cells (MNCs), dividing said suspension into two equal portions, cultivating MNCs from the first portion without a suppressor activator, and cultivating MNCs from the second portion with a suppressor activator, washing MNCs out of the culture medium and blocking proliferation, adding newly isolated MNCs from a normal donor into each of abovementioned portions of MNCs, stimulating with phytohemagglutinin in equal proportions to obtain test cultures, cultivating them and further evaluating proliferation in said test cultures and determining suppression value on the basis of the raties of proliferation levels in said test cultures (see By Lien Shov, Stanley A. Schwarts and Robert A. Good. Suppressor Cell Activity after Concanavalin A treatment of Lymphocytes from Normal Donors. J. Exp. Med., 1976, v.143, n.5, p. 1100-1110).
Nevertheless said known method also requires a hardly available and expensive foreign preparation, concanavalin A.
SUMMARY OF THE INVENTION
The main object of the present invention is to provide a less expensive process for determining a suppressor activity of human immune status by using a well available preparation which has an immune correcting activity and does not cause allergic reactions.
Said object is achieved by use of trophoblastic .beta.-I-glycoprotein (TBG) as a means for determining a suppressor component of human immune status, and the method of determination of a suppressor component of human immune status which method comprises collecting a sample of peripheral blood, obtaining a suspension of mononuclear cells (MNCs), dividing said suspension into two portions, cultivating the first portion without a suppressor activator, and cultivating the second one with a suppressor activator, washing MNCs out of the culture medium, blocking proliferation, adding into each of said MNC portions newly isolated MNCs obtained from a normal donor, stimulating with phytohemagglutinin in equal proportions to produce test cultures, cultivating said cultures, further evaluating the proliferation of said cultures and determining the suppression values based on the ratios of the levels of proliferation in test cultures. According to the present invention trophoblastic .beta.-I-glycoprotein (TBG) is used in dosages from 3 to 120 .mu.g
REFERENCES:
patent: 4275000 (1981-06-01), Ross
patent: 5013719 (1991-05-01), Bowlin
patent: 5118669 (1992-06-01), Noguchi et al.
patent: 5141849 (1992-08-01), Chou
patent: 5169835 (1992-12-01), Chan
Effect on Pregnancy and Hormonal Changes on the Activity of Rheumatoid Arthritis Monika Ostensen, et al, Dept. of Rheumatology, Institute of Clinical Medicine, Univ. of Tromso, Norway, Scand J. Rheum. 12:69 -72, 1983.
Suppressor Cell Activity After Concanavalin A Treatment of Lymphocytes from Normal Donors, Shou, et al, Journal of Experimental Medicine vol. 143, 1100-111;1976.
Inhibitory and Stimulatory Effects of Concanavalin on the Response of Mouse Spleen Cell Suspensions to Antigen, Richard Dutton, Journal of Experimental. Medicine vol. 138, pp. 1496-1505 (1973).
Immunochemical Identification of New Beta-1-Globulin in the Blood Serum of Pregnant Women, Bulletin of Experimental Biology and Medicine, 1970 No. 6, Medicina Publishers, Moscow, pp. 66-68, Figs. 1-2.
Human Trophoblastic Beta-1-Globulin and Chorionepithelioma, Tatarinov, et al, Onco Developmental Gene Expression, 1976, pp. 463-468.
Reference Preparation for Assay of Some Pregnancy and Cancer Associates Proteins, The Lancet, Oct. 11, 1980.
Shou, L., et al., "Suppressor Cell Activity After Concanavalin A Treatment of Lymphocytes From Normal Donors" The Journal of Experimental Medicine, vol. 143, 1976, pp. 1100-1109.
Dutton, R., "Inhibitory and Stimulatory Effects of Concanavalin A on the Response of Mouse Spleen Cell Suspensions to Antigen" The Journal of Experimental Medicine, vol. 138, 1973, pp. 1496 to 1505.
Shou et al., J.Exp.Med. 143(5):1100-1116, May 1976.
Gorlina et al, The Soviet Journal of Developmental Biology (English translation of Ontogenez) 14 (6):366-369, Sep. 1984.
Golovistikov et al., Immunologiya, 1:76-78, 1987.
Alikhanov Khallar Abdumuslimovich
Golovistikov Ivan Nikolaevich
Kacharava Leonid Yazonovich
Golovistikov Ivan Nikolaevich
Kacharava Leonid Yazonovich
Lazar-Wesley Eliane
Spector Lorraine
LandOfFree
Method of determining the suppressor cell component of human imm does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of determining the suppressor cell component of human imm, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of determining the suppressor cell component of human imm will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-729803